JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer

On November 13, 2026 Novocure (Nasdaq: NVCR) reported that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel in patients with unresectable, locally advanced pancreatic adenocarcinoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma, compared to GnP alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival for patients treated with TTFields therapy.

"One of the most debilitating complications of pancreatic cancer is pain. For clinicians, management of pain is a priority because it not only affects our patients’ quality of life but it can reduce compliance with anticancer treatments, negatively impacting survival outcomes," said Teresa Macarulla, MD, PhD, Head of Medical Oncology Department at Hospital Clínic Barcelona Comprehensive Cancer Centre. "The results from the PANOVA-3 trial found that in addition to improving overall survival, Tumor Treating Fields therapy provided clinically meaningful benefits on measures of pain outcomes and quality of life, which are important for clinical decision-making."

Secondary endpoints included quality of life outcomes measured using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with the pancreatic cancer specific PAN26 addendum scales. The EORTC QLQ-C30 and the PAN26 measure global health status and function as well as symptoms including pain (irrespective of cause), pancreatic pain, and gastrointestinal symptoms.

Results of the secondary endpoint measures demonstrated a statistically significant and clinically meaningful benefit across multiple measures of quality of life and pain outcomes. These results are detailed in the publication, Tumor Treating Fields and Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma – A Secondary Analysis of a Randomized Clinical Trial, View Source

"This publication in JAMA Network Open is an important step in providing the results from PANOVA-3 to the oncology community through a peer-reviewed resource," said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. "The results from the PANOVA-3 trial demonstrated the efficacy of Tumor Treating Fields therapy in locally advanced pancreatic cancer. We also evaluated and saw a positive and clinically meaningful effect from treatment with Tumor Treating Fields on pain, which can significantly affect patients’ quality of life. We believe these results can help inform clinicians and patients as they make treatment decisions."

TTFields therapy was well-tolerated in PANOVA-3, no new safety signals were observed, and device related safety outcomes were consistent with prior clinical studies using TTFields. Mild to moderate skin adverse events (AEs) were the most common device-related AEs.

(Press release, NovoCure, NOV 13, 2026, View Source [SID1234674787])